Document:

Amended Consulting Agreement - Peter C. Pang

 
Exhibit 4.1(c)

 
Amendment No. 1 to Consulting Agreement

Between Calypte Biomedical Corporation 
and Peter C. Pang 
 
This Agreement amends and modifies the Consulting Agreements between Calypte Biomedical Corporation (“Calypte” or the “Company”) and IPO Pang PC/Peter C. Pang (“Consultant”) and is effective as of April
11, 2003. 
 
Whereas, the Company desires to change the payment
terms on the contract for certain consulting services performed in 2002 and 2003, as well as future services, and Consultant is agreeable to such modification. 
 
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows: 
 

	 	1.	 	The Company acknowledges that as of March 31, 2003 it owes Consultant certain amounts for services rendered, payable in cash and totaling $59,442.50. It will now
convert this amount to stock issuable to Consultant individually, or his designee, based on the closing market price of Calypte Common Stock on the effectiveness date of the registration statement in Section 2 below. 

 

	 	2.	 	In consideration for this modification, the Company agrees to register the shares with the upcoming S-8 filing during April 2003. 

 

	 	3.	 	The Company agrees to register 3 million shares for such purposes. After satisfying the above commitment, shares can be used at the option of the Consultant, upon
written notice, to pay for future services under the ongoing consulting agreement. Such stock would be payable at the then current market price on the date of the written notice. 

 

	 	4.	 	All other terms and conditions of the existing Consultant Agreements remain unchanged. 

 

	 Consultant:
	 	 	 	 CALYPTE BIOMEDICAL CORPORATION

	
	 /s/    PETER C. PANG

	 	 	 	 By:
	 	 /s/    RICHARD D. BROUNSTEIN

	 Peter C. Pang
	 	 	 	 	 	 Richard D. Brounstein
 EVP & CFO

 

19Consulting Agreement

 
Exhibit 4.1(d)

 
[Voter Connect Communications,
Inc. 
2377 Gold Meadow Way, Suite 210 
Gold River, California 95670] 
 
Consulting Agreement of April 3, 2003 
 

	 	TO:	 	Nancy E. Katz 

 

	 	FR:	 	Tom Bernthal, Chris St. Hilaire and Tony Russo 

 

	 	Cc:	 	Anthony Cataldo 

 

	 	RE:	 	Proposed Scope of Work 

 
Thank you for the opportunity to learn more about Calypte’s innovative products and marketing endeavors. We are excited about the
prospect of helping “open doors” to those and other markets to create additional value for the company. 
 
Our efforts would be focused in three primary areas: building networks to new markets, increasing awareness and acceptance among opinion
leaders and breaking down barriers or obstacles to market growth. 
 
Below is a proposed scope of work that outlines ways in which we believe our contacts, background and experience will help Calypte accomplish its marketing goals. 
 
Building Networks to New Markets 
 

	 	•	 	Participate in planning and marketing meetings to better understand Calypte’s marketing plans and better assess opportunities. 

 

	 	•	 	Provide names and introductions to people in all levels of government who can help open new markets and opportunities for 

 

20 

 
Calypte. These
initial introductions would be in state and national government, the military, the corrections industry, as well as agencies and elected officials to be defined in our overall plan. 
 

	 	•	 	Provide access and present opportunities with other health care providers, including hospital and insurance companies – as well as state and national budget
decision-makers concerned with stretching tax revenue. 

 

	 	•	 	Provide “message” recommendations for approaching different industries and governments, and specific individuals in each. 

 

	 	•	 	Prepare written materials for presentation to decision makers. 

 

	 	•	 	Facilitate follow-up and information sharing after initial meetings to move initial contacts to real support and action for Calypte. 

 
Increasing Awareness and Acceptance  
 

	 	•	 	Identify and secure opportunities for Calypte representatives to present the company’s products – including medical, dental, health care, public health,
service and taxpayer groups. 

 

	 	•	 	Schedule tours for public officials and opinion leaders to visit Calypte production labs and facilities, as well as to hear briefings from Calypte’s corporate
officers and research directors. 

 

	 	•	 	Identify opinion leaders key to advancing Calypte’s products and market growth, and develop ongoing communications to share 

 

21 

 

	 	important	 	information about the company. 

 

	 	•	 	Provide background briefing materials before all tours, meetings and presentations to ensure Calypte representatives hit the “right buttons” to advance
potential marketing opportunities. 

 

	 	•	 	Help prepare presentation materials – tailored to target audiences – to ensure our product is presented with the respective industry in mind.

 

	 	•	 	Identify and secure important product endorsements from respected groups and leaders to provide added credibility and acceptance to Calypte products.

 
Agency Compensation

 
We understand the tight cash-flow position
Calypte finds itself in today. At the same time, we appreciate the upside potential in terms of stock market value, should Calypte’s products become mainstreamed into the health care industry and public health arena. 
 
While our ordinary monthly retainer fees would be $25,000 per
month, we recommend the compensation package below – recognizing that we are taking some risk in providing services for strictly stock which may or may not provide a return on our investment. 
 
Therefore, we propose compensation as outlined below:

 

	 	1.	 	An assignment of shares of Calypte common stock valued at $75,000 (2,500,000 shares) upon signing a six-month contract that 

 

22 

would serve as compensation for the first three months of services (April, May and June).
Afterwards, the contract would be cancelable upon 15 days written notice by either party. We agree to this stock grant, in lieu of cash compensation, based on the representation that the company has shares of common stock outstanding. 
 

	 	2.	 	Earn and share $16,665/month, payable in shares of Calypte stock monthly from July through September 2003, as compensation for our services – payable at the
first of each month at the market price of the stock each month. . The company agrees to initially register 1 million shares for these services as part of the piggyback rights in 4 below. 

 

	 	3.	 	Earn up to another $75,000, payable in shares of Calypte stock based on meeting certain mutually agreed performance goals to be outlined in our contract. These would
include scheduling designated meetings, providing opportunities to bid on specific contracts, earning product endorsements by credible third party groups, and securing actual contracts. The company agrees to initially register 1.5 million shares for
such performance goals as part of the piggyback rights in 4 below. 

 

	 	4.	 	The shares should be deemed fully-paid and non assessable and will have piggyback registration rights in the next S-8 or domestic S-2 filing.

 

	 	5.	 	The share numbers above will be adjusted for any stock splits or dividends. 

 

23 

We have signed this memorandum, which will be followed with a more detailed contract once we have agreed
to a value for meeting certain mutually agreed performance goals noted in #2. 
 
Thank you for the opportunity to submit this scope of work. We are very excited about the prospect of working with you to open new markets and create market value. 
 

	 Very truly yours

	
	 /s/    ANTHONY RUSSO
      

	 Tom Bernthal, Christ, St, Hilare and Tony Russo

 

	 Agreed To:         

	
	 CALPTYE BIOMEDICAL
CORPORATION

 

	 /s/    NANCY E. KATZ
      

	 Nancy E. Katz

	 President and Chief Executive Officer

 
 
 

24Amended Consulting Agreement - Sadegh Panahi

 
Exhibit 4.1(e)

 
Amendment No. 3 to Consulting Agreement

Between 
Calypte Biomedical Corporation 
And 
Sadegh Panahi 
 
This Agreement amends and modifies the Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Sadegh Panahi (“Consultant”) dated November 20, 2002 and is
effective as of April 4, 2003. 
 
Whereas, the Company desires to
extend the time period during which Consultant will provide services to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to extending the time for providing such services. 
 
Now therefore, in consideration of the premises and mutual promises set forth
herein, the parties hereto agree as follows: 
 

	 	1.	 	The term of Consultant’s Consulting Agreement shall be extended and, by virtue of this Amendment, shall terminate on September 30, 2003 rather than July 20,
2003. 

 

	 	2.	 	The Company will immediately grant Consultant a warrant to purchase five million (5,000,000) shares of the common stock of the Company at an exercise price of $0.025
per share, or an aggregate purchase price of $250,000. The Company will also immediately amend the February 14, 2003 warrant to purchase 3,000,000 shares of the registered stock of the Company from $0.05 per share, to $0.025 per share. Both warrants
will be immediately exercisable upon grant and will expire on June 30, 2003. All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. 

 

	 	3.	 	All other terms and conditions of the Consultant Agreement dated November 20, 2002 remain unchanged. 

 

	 Consultant:
	 	 CALYPTE BIOMEDICAL CORPORATION

	 	 	 	 	 
	
	 	 	 /s/    SADEGH
PANAHI        

	 	 By:
	 	 /s/    RICHARD BROUNSTEIN
        

	 	 	 Sadegh Panahi
	 	 	 	 Richard D. Brounstein
 Executive Vice President, CFO

 

25Amended Consulting Agreement - Jonathan Bernstein

 
Exhibit 4.1(f)

 
Amendment 1 to Consulting Agreement 
 
Between Calypte Biomedical Corporation and Jonathan Bernstein

 
This Agreement amends and modifies the Consulting Agreement
between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Jonathan Bernstein (“Consultant”) dated December 5, 2002 and is effective as of April 4, 2003. 
 
Whereas, the Company desires to change the payment terms on the contract and
Consultant is agreeable to such modification. 
 
Now therefore, in
consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows: 
 

	 	1.	 	The Company acknowledges that it owes Consultant $43,000.00 for services rendered, payable in cash. It will now convert these payments to stock issuable to
Consultant individually, or his designee, based on 95% of the closing market price of Calypte Common Stock on the effectiveness date of the registration statement in Section 2 below. 

 

	 	2.	 	In consideration for this modification, the Company agrees to register the shares with the upcoming S-8 filing during early April 2003. If the filing occurs
thereafter, Consultant has the option to accept only cash. Further amounts owed and remaining after the issuance of the stock at the market value, as defined above, if any, will be payable in cash by the end of May. 

 

	 	3.	 	The Company agrees to register 1.7 million shares for such purposes. 

 

	 	4.	 	All other terms and conditions of the Consultant Agreement dated December 5, 2002 remain unchanged. 

 

	 Consultant:
	 	 CALYPTE BIOMEDICAL
CORPORATION

	 	 	 
	
	 	 	 /s/    JONATHAN
BERNSTEIN        

	 	 By:
	 	 /s/    RICHARD
BROUNSTEIN        

	 	 	 Jonathan Bernstein
	 	 	 	 Richard D. Brounstein
 Executive Vice President, CFO

 
 
 

26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]